City Therapeutics, Inc. Common Stock Total Liabilities

Latest as of June 2026: $340.33 Million USD

City Therapeutics, Inc. Common Stock total liabilities. Based on the latest financial reports, City Therapeutics, Inc. Common Stock (CTY) has total liabilities worth $340.33 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check CTY asset resilience ratio to evaluate the company's liquid asset resilience ratio.

Total Liabilities of City Therapeutics, Inc. Common Stock (2005–2025)

Total liabilities of City Therapeutics, Inc. Common Stock from 2005 to 2025. This chart illustrates how City Therapeutics, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data.

City Therapeutics, Inc. Common Stock Competitors by Total Liabilities

The table below lists competitors of City Therapeutics, Inc. Common Stock ranked by their total liabilities.

Company Country Total Liabilities
Foshan Electrical and Lighting Co Ltd
SHE:000541
China CN¥5.95 Billion
BrightView Holdings
NYSE:BV
USA $1.69 Billion
Amerigo Resources Ltd.
TO:ARG
Canada CA$84.02 Million
Daily Journal Corp
NASDAQ:DJCO
USA $134.18 Million
Ningbo Sunrise Elc Technology Co Ltd Class A
SHE:002937
China CN¥656.02 Million
SpartanNash Co
NASDAQ:SPTN
USA $1.82 Billion
Hunan New Wellful Co Ltd
SHG:600975
China CN¥8.74 Billion
ATEX Resources Inc.
V:ATX
Canada CA$10.29 Million

Liability Composition Analysis (2005–2025)

This chart breaks down City Therapeutics, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see City Therapeutics, Inc. Common Stock (CTY) total assets.

Liquidity & Leverage Metrics

City Therapeutics, Inc. Common Stock Total Liabilities Ratios Explained

City Therapeutics, Inc. Common Stock total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric Value Description
Current Ratio 2.71 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity -2.58 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 1.63 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how City Therapeutics, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for City Therapeutics, Inc. Common Stock (2005–2025)

The table below shows the annual total liabilities of City Therapeutics, Inc. Common Stock from 2005 to 2025.

Year Total Liabilities Change
2025-12-31 $234.42 Million +34.13%
2024-12-31 $174.78 Million -98.39%
2019-12-31 $10.88 Billion +1.56%
2018-12-31 $10.71 Billion -7.08%
2017-12-31 $11.53 Billion -7.43%
2016-12-31 $12.46 Billion -0.84%
2015-12-31 $12.56 Billion -5.36%
2014-12-31 $13.27 Billion -2.43%
2013-12-31 $13.61 Billion -2.62%
2012-12-31 $13.97 Billion -7.14%
2011-12-31 $15.04 Billion +3.64%
2010-12-31 $14.52 Billion -1.42%
2009-12-31 $14.73 Billion +0.47%
2008-12-31 $14.66 Billion +1.64%
2007-12-31 $14.42 Billion -2.17%
2006-12-31 $14.74 Billion -3.25%
2005-12-31 $15.23 Billion --

About City Therapeutics, Inc. Common Stock

NASDAQ:CTY USA Biotechnology
Market Cap
$911.01 Million
Market Cap Rank
#9050 Global
#2589 in USA
Share Price
$18.10
Change (1 day)
-4.64%
52-Week Range
$16.41 - $22.14
All Time High
$22.14
About

City Therapeutics, Inc. operates as a biopharmaceutical company focused on developing RNA interference (RNAi)-based medicines by engineering RNAi trigger molecules. The company develops RNAi-based medicines using engineered small interfering RNAs (siRNAs) and is building a pipeline of therapeutics targeting diseases across multiple therapeutic areas, including ophthalmologic conditions such as re… Read more